Claims for Patent: 10,213,486

Summary for Patent: 10,213,486

Title:	Formulations of diluted amino acid segments and methods for making same
Abstract:	A formulation of a diluted amino acid fragment is prepared by mixing an amino acid fragment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid fragment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
Inventor(s):	Carter; Jacob L. (Pleasant Grove, UT), Lephart; Edwin Douglas (Orem, UT)
Assignee:	Deseret Biologicals, Inc. (Sandy, UT)
Application Number:	15/470,239
Patent Claims:	1. A method comprising: mixing an amino acid fragment and a diluting agent to form a mixture; and serially diluting at least a portion of the mixture to produce a diluted formulation having a concentration of the amino acid fragment that is no more than 1.times.10.sup.-10 w/w; wherein the amino acid fragment includes a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin; and wherein the amino acid fragment is not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 2. The method of claim 1 wherein the peptide sequence includes at least ten amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 3. The method of claim 1 wherein the peptide sequence includes at least fifteen amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 4. The method of claim 1 wherein the peptide sequence includes at least twenty amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 5. The method of claim 1 wherein the peptide sequence is a first peptide sequence, the amino acid fragment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 6. The method of claim 5 wherein the second peptide sequence is the same as the N-terminal end of the alpha subunit of human chorionic gonadotropin. 7. The method of claim 5 wherein the second peptide sequence includes at least ten amino acids and is the same as the terminal end of the alpha subunit of human chorionic gonadotropin. 8. The method of claim 1 wherein at least 50% w/w of the amino acid fragments in the mixture each include a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin, and wherein the at least 50% w/w of the amino acid fragments are not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 9. The method of claim 1 wherein serially diluting at least a portion of the mixture includes producing successive, increasingly dilute mixtures and vigorously mixing each increasingly dilute mixture. 10. The method of claim 1 wherein serially diluting at least a portion of the mixture includes producing successive, increasingly dilute mixtures using the same dilution ratio for each increasingly dilute mixture. 11. The method of claim 1 wherein the mixture is serially diluted using an average dilution ratio of no more than approximately 1:5. 12. The method of claim 1 wherein the mixture is serially diluted at least three times. 13. The method of claim 1 wherein the potency of the diluted formulation is at least 20V, 10X, or 5C. 14. A method comprising: mixing an amino acid fragment and a diluting agent to form a mixture; repeatedly diluting at least a portion of the mixture to produce successive, increasingly dilute mixtures including a dilute mixture having a concentration of the amino acid fragment that is no more than 1.times.10.sup.-10 w/w; and succussing each increasingly dilute mixture; wherein the amino acid fragment includes a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin; and wherein the amino acid fragment is not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 15. The method of claim 14 wherein the peptide sequence includes at least ten amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 16. The method of claim 14 wherein the peptide sequence includes at least fifteen amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 17. The method of claim 14 wherein the peptide sequence includes at least twenty amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 18. The method of claim 14 wherein the peptide sequence is a first peptide sequence, the amino acid fragment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 19. The method of claim 14 wherein at least 50% w/w of the amino acid fragments in the mixture each include a peptide sequence of at least five amino acids that is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin, and wherein the at least 50% w/w of the amino acid fragments are not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 20. The method of claim 14 wherein the same dilution ratio is used to produce each increasingly dilute mixture. 21. The method of claim 14 wherein each increasingly dilute mixture is diluted using an average dilution ratio of no more than approximately 1:5. 22. The method of claim 14 wherein repeatedly diluting at least a portion of the first mixture produces at least three increasingly dilute mixtures. 23. A packaged formulation comprising: a container; a homeopathic formulation inside the container; and a label attached to the container; wherein the homeopathic formulation is produced by the method recited in claim 1. 24. The packaged formulation of claim 23 wherein the peptide sequence includes at least ten amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 25. The packaged formulation of claim 23 wherein the peptide sequence includes at least fifteen amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 26. The packaged formulation of claim 23 wherein the peptide sequence includes at least twenty amino acids and is the same as the N-terminal end of the beta subunit of human chorionic gonadotropin. 27. The packaged formulation of claim 23 wherein the peptide sequence is a first peptide sequence, the amino acid fragment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 28. The packaged formulation of claim 27 wherein the second peptide sequence is the same as the N-terminal end of the alpha subunit of human chorionic gonadotropin. 29. The packaged formulation of claim 27 wherein the second peptide sequence includes at least ten amino acids and is the same as the terminal end of the alpha subunit of human chorionic gonadotropin. 30. The packaged formulation of claim 23 wherein the homeopathic formulation is liquid. 31. The packaged formulation of claim 23 wherein the homeopathic formulation is in the form of a pellet, tablet, or capsule.

Details for Patent 10,213,486

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2037-03-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2037-03-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2037-03-27
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2037-03-27
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2037-03-27
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2037-03-27

International Patent Family for US Patent 10,213,486

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012129519
United States of America	9603898
United States of America	2017196939
United States of America	2012245084